The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / U.S. Justice Department Has Concerns about Aetna-Humana Deal

U.S. Justice Department Has Concerns about Aetna-Humana Deal

July 9, 2016 • By Caroline Humer & Diane Bartz

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—The U.S. Department of Justice has significant concerns about Aetna Inc.’s proposed acquisition of health insurer Humana Inc., a source familiar with the situation said on Thursday, and shares of Humana fell more than 11%.

You Might Also Like
  • Aetna’s Deal for Humana May Push Up Costs for Seniors
  • U.S. Regulators Sue to Block Anthem-Cigna & Aetna-Humana Mergers
  • U.S. Antitrust Officials Poised to Block Anthem, Aetna Deals

Aetna’s purchase of Humana would combine two of the largest providers of Medicare Advantage plans for elderly people, and investors have long been concerned the deal might pose a competition issue for antitrust regulators.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The Justice Department is also reviewing Anthem Inc’s proposed purchase of Cigna Corp, and investors are worried it will fail because of its impact on competition in the employer insurance market. Together, the two deals will decrease the number of national health insurers to three from five.

News of the Justice Department’s significant concerns come as the department is due to meet with officials from Aetna and Humana on Friday, as first reported by antitrust trade publication MLex.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The source, who was not authorized to speak publicly about the matter, confirmed the department’s concerns, but did not expound on the exact nature of its worries.

However, the issue raised investor worries on both deals.

Jeff Jonas, portfolio manager for Gabelli Funds, which owns Humana and Cigna shares, says that he believes that the Aetna-Humana deal still has a chance to go through with divestitures because there are plenty of buyers for the assets.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“Even after today’s drop, I don’t think people are totally ruling out Aetna and Humana,” Jonas says.

Reuters reported last week that Aetna had begun a process to divest about $1 billion of Medicare Advantage assets to address antitrust concerns.

Antitrust regulators are mainly focused on whether the deal would limit consumer choices for Medicare Advantage health plans for the elderly.

Aetna has argued that Medicare Advantage competes not just with other Medicare Advantage plans, but with traditional Medicare, according to a different source familiar with the matter.

Aetna announced its plans to buy Humana Inc. last summer in a deal now worth about $34 billion. Anthem’s deal for Cigna was announced a few weeks later.

Humana was not immediately available for comment.

Filed Under: Legal, Professional Topics Tagged With: Aetna Inc., Health Insurance, Humana Inc., Medicare Advantage, merger

You Might Also Like:
  • Aetna’s Deal for Humana May Push Up Costs for Seniors
  • U.S. Regulators Sue to Block Anthem-Cigna & Aetna-Humana Mergers
  • U.S. Antitrust Officials Poised to Block Anthem, Aetna Deals
  • Aetna CEO Warned It Would Cut Obamacare If Humana Deal Was Blocked

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.